



## Clinical trial results:

**A phase III, single-group, open-label, multicentre study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals' combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b (DTPa-IPV/Hib) vaccine Infanrix-IPV+Hib administered as a booster vaccine dose in healthy Vietnamese toddlers.**

### Summary

EudraCT number	2013-002538-18
Trial protocol	Outside EU/EEA
Global end of trial date	09 April 2013

### Results information

Result version number	v2 (current)
This version publication date	16 September 2018
First version publication date	03 July 2015
Version creation reason	<ul style="list-style-type: none"><li>• Correction of full data set</li><li>Minor corrections of the full study results.</li></ul>

### Trial information

#### Trial identification

Sponsor protocol code	115389
-----------------------	--------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01577732
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	06 August 2013
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 April 2013
Global end of trial reached?	Yes
Global end of trial date	09 April 2013
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To assess the safety and reactogenicity of the study vaccine in terms of solicited symptoms, unsolicited symptoms and serious adverse events (SAEs).

Protection of trial subjects:

All subjects were supervised closely for at least 30 minutes following vaccination with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Vaccines were administered only to eligible subjects that had no contraindications to any components of the vaccines. Subjects were followed-up from the time the subject consents to participate in the study until she/he is discharged.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	08 December 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Vietnam: 321
Worldwide total number of subjects	321
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	321
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

321 subjects were screened and allocated a subject number for the study, out of which 300 participated in the study and received the study vaccination.

### Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Infanrix-IPV+Hib Group
-----------	------------------------

Arm description:

Subjects aged between, and including 12 and 24 months received a single dose of Infanrix-IPV+Hib. The vaccine was administered intramuscularly in the anterolateral side of the thigh.

Arm type	Experimental
Investigational medicinal product name	Infanrix-IPV+Hib
Investigational medicinal product code	
Other name	DTPa-IPV/Hib
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose administered intramuscularly (IM) into the anterolateral side of the right thigh, at 12-14 months of age.

<b>Number of subjects in period 1<sup>[1]</sup></b>	Infanrix-IPV+Hib Group
Started	300
Completed	300

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 321 subjects were screened and allocated a subject number for the study, out of which 300 participated in the study and received the study vaccination.

## Baseline characteristics

### Reporting groups

Reporting group title	Infanrix-IPV+Hib Group
-----------------------	------------------------

Reporting group description:

Subjects aged between, and including 12 and 24 months received a single dose of Infanrix-IPV+Hib. The vaccine was administered intramuscularly in the anterolateral side of the thigh.

Reporting group values	Infanrix-IPV+Hib Group	Total	
Number of subjects	300	300	
Age categorical Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous Units: months			
arithmetic mean	15.8		
standard deviation	± 2.96	-	
Gender categorical Units: Subjects			
Female	143	143	
Male	157	157	

## End points

### End points reporting groups

Reporting group title	Infanrix-IPV+Hib Group
Reporting group description:	
Subjects aged between, and including 12 and 24 months received a single dose of Infanrix-IPV+Hib. The vaccine was administered intramuscularly in the anterolateral side of the thigh.	

### Primary: Number of subjects reporting solicited local symptoms

End point title	Number of subjects reporting solicited local symptoms <sup>[1]</sup>
End point description:	
Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of any local symptom regardless of intensity grade.	
End point type	Primary
End point timeframe:	
Within the 4-day (Days 0-3) follow up period after vaccination.	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	Infanrix-IPV+Hib Group			
Subject group type	Reporting group			
Number of subjects analysed	300			
Units: Subjects				
Any Pain	95			
Any Redness	82			
Any Swelling	52			

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects reporting solicited general symptoms

End point title	Number of subjects reporting solicited general symptoms <sup>[2]</sup>
End point description:	
Solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss of Appetite and Fever, defined as axillary temperature higher than (>) 37.5 degrees Celsius (°C). Any = occurrence of a general symptom regardless of intensity grade or relationship to study vaccination.	
End point type	Primary
End point timeframe:	
Within the 4-day (Days 0-3) follow up period after vaccination.	

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	Infanrix- IPV+Hib Group			
Subject group type	Reporting group			
Number of subjects analysed	300			
Units: Subjects				
Any Drowsiness	52			
Any Irritability/fussiness	108			
Any Loss of appetite	115			
Any Fever	101			

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of subjects reporting any unsolicited adverse events (AEs)

End point title	Number of subjects reporting any unsolicited adverse events (AEs) <sup>[3]</sup>
-----------------	--

End point description:

An unsolicited AE was any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of an AE regardless of intensity grade or relationship to study vaccination.

End point type	Primary
----------------	---------

End point timeframe:

Within the 31-day (Days 0-30) follow up period after vaccination.

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	Infanrix- IPV+Hib Group			
Subject group type	Reporting group			
Number of subjects analysed	300			
Units: Subjects				
Any AE(s)	107			

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of subjects reporting any serious adverse events (SAEs)

End point title	Number of subjects reporting any serious adverse events (SAEs) <sup>[4]</sup>
-----------------	---

End point description:

SAEs assessed included medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity. Any SAE = any SAE regardless of assessment of relationship to study vaccination.

End point type	Primary
----------------	---------

End point timeframe:

During the entire study period (Days 0-30).

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

<b>End point values</b>	Infanrix- IPV+Hib Group			
Subject group type	Reporting group			
Number of subjects analysed	300			
Units: Subjects				
Any SAE(s)	1			

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Solicited symptoms: 4-day (Days 0-3) follow-up period after booster vaccination; unsolicited AEs: 31-day (Days 0-30) follow-up period after booster vaccination; SAEs: during the entire study period (Days 0-30).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	16.0

### Reporting groups

Reporting group title	Infanrix-IPV+Hib Group
-----------------------	------------------------

Reporting group description:

Subjects aged between, and including 12 and 24 months received a single dose of Infanrix-IPV+Hib. The vaccine was administered intramuscularly in the anterolateral side of the thigh.

Serious adverse events	Infanrix-IPV+Hib Group		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 300 (0.33%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Nervous system disorders			
Convulsion			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 300 (0.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Pneumonia			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 300 (0.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %



<b>Non-serious adverse events</b>	Infanrix-IPV+Hib Group		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	211 / 300 (70.33%)		
General disorders and administration site conditions			
Pain			
subjects affected / exposed	95 / 300 (31.67%)		
occurrences (all)	95		
Redness			
subjects affected / exposed	82 / 300 (27.33%)		
occurrences (all)	82		
Swelling			
subjects affected / exposed	52 / 300 (17.33%)		
occurrences (all)	52		
Drowsiness			
subjects affected / exposed	52 / 300 (17.33%)		
occurrences (all)	52		
Irritability/fussiness			
subjects affected / exposed	108 / 300 (36.00%)		
occurrences (all)	108		
Loss of appetite			
subjects affected / exposed	115 / 300 (38.33%)		
occurrences (all)	115		
Fever			
subjects affected / exposed	101 / 300 (33.67%)		
occurrences (all)	101		
Respiratory, thoracic and mediastinal disorders			
Cough			
alternative assessment type: Non-systematic			
subjects affected / exposed	48 / 300 (16.00%)		
occurrences (all)	48		

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported